We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Global License Agreement for the Commercialization of Vitreolysis Therapy

Credit: Daniil Kuzelev via Unsplash

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Global License Agreement for the Commercialization of Vitreolysis Therapy"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Inceptua – pharmaceutical company and service partner – and biopharmaceutical company Oxurion have announced a global license agreement for the commercialization of JETREA®, a first-in-class pharmacological vitreolysis therapy approved for treatment of symptomatic vitreomacular adhesion or vitreomacular traction.

“We are happy to assume the work of providing this important treatment option to patients and physicians. This global license agreement for JETREA® is an important building block for Inceptua. As both a pharmaceutical company and a service partner, we are committed to bringing treatments to patients in need through a business model spanning throughout the product lifecycle and building on our combined expertise in both commercialization of specialty and rare disease products, clinical trial comparator sourcing, packaging, labeling, and distribution solutions, as well as access programs for pre-approval and unlicensed medicines,” says Stefan Fraenkel, CEO, Inceptua Group.

JETREA® was launched in early 2013, and over 35,000 patients have been treated with the product to-date with real-world clinical data confirming that the drug is a safe and effective early treatment for a well-identified group of patients suffering from symptomatic vitreomacular adhesion or vitreomacular traction.

The EU Marketing Authorization and global distribution rights will be transferred to the Inceptua Group during 2020, and will vary by region. In Europe, the Marketing Authorization transfer is expected to be completed by Summer 2020.